963 Shares in Teleflex Incorporated (NYSE:TFX) Bought by Exencial Wealth Advisors LLC

Exencial Wealth Advisors LLC purchased a new stake in shares of Teleflex Incorporated (NYSE:TFXGet Rating) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 963 shares of the medical technology company’s stock, valued at approximately $316,000.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. HighTower Advisors LLC grew its holdings in Teleflex by 0.8% during the third quarter. HighTower Advisors LLC now owns 4,652 shares of the medical technology company’s stock worth $1,759,000 after buying an additional 36 shares in the last quarter. Veritable L.P. boosted its holdings in Teleflex by 4.9% during the third quarter. Veritable L.P. now owns 793 shares of the medical technology company’s stock worth $299,000 after purchasing an additional 37 shares during the last quarter. Mutual of America Capital Management LLC increased its position in shares of Teleflex by 0.7% during the third quarter. Mutual of America Capital Management LLC now owns 6,149 shares of the medical technology company’s stock valued at $2,315,000 after acquiring an additional 42 shares during the last quarter. Harel Insurance Investments & Financial Services Ltd. increased its position in shares of Teleflex by 62.9% during the 4th quarter. Harel Insurance Investments & Financial Services Ltd. now owns 114 shares of the medical technology company’s stock valued at $38,000 after purchasing an additional 44 shares during the last quarter. Finally, Veriti Management LLC increased its position in Teleflex by 7.5% in the fourth quarter. Veriti Management LLC now owns 884 shares of the medical technology company’s stock worth $290,000 after buying an additional 62 shares during the last quarter. Hedge funds and other institutional investors own 92.21% of the company’s stock.

Shares of NYSE TFX opened at $292.76 on Wednesday. The company has a debt-to-equity ratio of 0.46, a current ratio of 2.28 and a quick ratio of 1.53. The stock’s 50-day moving average is $322.40 and its two-hundred day moving average is $324.54. The company has a market cap of $13.73 billion, a price-to-earnings ratio of 28.45, a price-to-earnings-growth ratio of 1.85 and a beta of 1.13. Teleflex Incorporated has a 1-year low of $256.77 and a 1-year high of $428.36.

Teleflex (NYSE:TFXGet Rating) last released its quarterly earnings results on Thursday, April 28th. The medical technology company reported $2.88 EPS for the quarter, topping the consensus estimate of $2.72 by $0.16. Teleflex had a return on equity of 17.24% and a net margin of 17.31%. The company had revenue of $641.70 million for the quarter, compared to analyst estimates of $631.89 million. During the same quarter in the previous year, the company posted $2.87 earnings per share. The firm’s revenue was up 1.2% compared to the same quarter last year. Equities research analysts anticipate that Teleflex Incorporated will post 13.98 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, June 15th. Shareholders of record on Monday, May 16th will be issued a $0.34 dividend. This represents a $1.36 dividend on an annualized basis and a yield of 0.46%. The ex-dividend date is Friday, May 13th. Teleflex’s dividend payout ratio (DPR) is currently 13.22%.

A number of brokerages have weighed in on TFX. Morgan Stanley decreased their target price on Teleflex from $383.00 to $378.00 and set an “equal weight” rating on the stock in a research note on Friday, February 25th. TheStreet downgraded shares of Teleflex from a “b-” rating to a “c+” rating in a research note on Monday. StockNews.com raised Teleflex from a “hold” rating to a “buy” rating in a research note on Wednesday, May 11th. Raymond James lowered their target price on Teleflex from $391.00 to $370.00 and set an “outperform” rating for the company in a research note on Wednesday, February 23rd. Finally, Piper Sandler raised their price objective on Teleflex from $320.00 to $335.00 in a research report on Thursday, February 24th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat, Teleflex has an average rating of “Buy” and an average price target of $388.46.

Teleflex Company Profile (Get Rating)

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.

Further Reading

Want to see what other hedge funds are holding TFX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teleflex Incorporated (NYSE:TFXGet Rating).

Institutional Ownership by Quarter for Teleflex (NYSE:TFX)

Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with MarketBeat.com's FREE daily email newsletter.